Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 126,700 shares of the biopharmaceutical company’s stock after acquiring an additional 15,900 shares during the quarter. California Public Employees Retirement System owned about 0.15% of Alnylam Pharmaceuticals worth $10,106,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ALNY. FMR LLC boosted its holdings in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 13.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after acquiring an additional 441,957 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.9% in the 2nd quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock worth $273,681,000 after acquiring an additional 96,805 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. lifted its holdings in shares of Alnylam Pharmaceuticals by 20.5% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock worth $81,488,000 after acquiring an additional 270,000 shares during the last quarter. Hedge funds and other institutional investors own 94.25% of the company’s stock.

In other news, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is owned by company insiders.

Several brokerages recently weighed in on ALNY. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, September 11th. Nomura initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 14th. They issued a “reduce” rating and a $56.00 price objective on the stock. ValuEngine raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Instinet began coverage on shares of Alnylam Pharmaceuticals in a report on Friday, September 15th. They issued a “reduce” rating and a $56.00 target price for the company. Three analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $100.80.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 121.885 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $126.16. The company has a 50-day moving average of $100.82 and a 200 day moving average of $77.74. The firm’s market cap is $11.18 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. Alnylam Pharmaceuticals’s revenue was up 82.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.05) EPS. Equities analysts predict that

A number of other institutional investors and hedge funds have also bought and sold shares of ALNY. FMR LLC boosted its holdings in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 13.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after acquiring an additional 441,957 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.9% in the 2nd quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock worth $273,681,000 after acquiring an additional 96,805 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. lifted its holdings in shares of Alnylam Pharmaceuticals by 20.5% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock worth $81,488,000 after acquiring an additional 270,000 shares during the last quarter. Hedge funds and other institutional investors own 94.25% of the company’s stock.

In other news, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is owned by company insiders.

Several brokerages recently weighed in on ALNY. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, September 11th. Nomura initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 14th. They issued a “reduce” rating and a $56.00 price objective on the stock. ValuEngine raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Instinet began coverage on shares of Alnylam Pharmaceuticals in a report on Friday, September 15th. They issued a “reduce” rating and a $56.00 target price for the company. Three analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $100.80.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 121.885 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $126.16. The company has a 50-day moving average of $100.82 and a 200 day moving average of $77.74. The firm’s market cap is $11.18 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. Alnylam Pharmaceuticals’s revenue was up 82.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.05) EPS. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current year.

WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by California Public Employees Retirement System” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/10/17/alnylam-pharmaceuticals-inc-alny-stake-increased-by-california-public-employees-retirement-system.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply